Global Human Microbiome Based Drugs and Diagnostics Market Size, Status and Forecast 2025


Report ID : RNR-228239 Category : Biotechnology Published Date : 2018
Publisher : QYResearch Pages : 91 Format : PDF
The modern approach involves exploiting the interaction between humans and the bacteria that live in or on the body to develop new drugs and therapies to treat chronic diseases such as diabetes. These microbiomes derived drugs help the physician in better diagnosis of the illness.
Rising cases of chronic diseases such as diabetes, disorders at early stage and the ability of the drugs to diagnose them and increased awareness among people to maintain healthy lifestyle is driving the growth of this market.

In 2017, the global Human Microbiome Based Drugs and Diagnostics market size was xx million US$ and it is expected to reach xx million US$ by the end of 2025, with a CAGR of xx% during 2018-2025.

This report focuses on the global Human Microbiome Based Drugs and Diagnostics status, future forecast, growth opportunity, key market and key players. The study objectives are to present the Human Microbiome Based Drugs and Diagnostics development in United States, Europe and China.

The key players covered in this study

    Second Genome Inc.

    Enterome Bioscience

    Yakult

    DuPont

    Vedanta BioSciences

    Metabiomics Corporation

    ViThera Pharmaceuticals

    MicroBiome Therapeutics LLC

    Osel

    Merck

Market segment by Type, the product can be split into

    Therapeutics

    Diagnostics

Market segment by Application, split into

    Clinical Research Institutes

    Hospital

    Surgical Centers

    Others

Market segment by Regions/Countries, this report covers

    United States

    Europe

    China

    Japan

    Southeast Asia

    India

    Central & South America

The study objectives of this report are:

    To analyze global Human Microbiome Based Drugs and Diagnostics status, future forecast, growth opportunity, key market and key players.

    To present the Human Microbiome Based Drugs and Diagnostics development in United States, Europe and China.

    To strategically profile the key players and comprehensively analyze their development plan and strategies.

    To define, describe and forecast the market by product type, market and key regions.

In this study, the years considered to estimate the market size of Human Microbiome Based Drugs and Diagnostics are as follows:

    History Year: 2013-2017

    Base Year: 2017

    Estimated Year: 2018

    Forecast Year 2018 to 2025

For the data information by region, company, type and application, 2017 is considered as the base year. Whenever data information was unavailable for the base year, the prior year has been considered.
Table of Contents
1 Report Overview

    1.1 Study Scope

    1.2 Key Market Segments

    1.3 Players Covered

    1.4 Market Analysis by Type

        1.4.1 Global Human Microbiome Based Drugs and Diagnostics Market Size Growth Rate by Type (2013-2025)

        1.4.2 Therapeutics

        1.4.3 Diagnostics

    1.5 Market by Application

        1.5.1 Global Human Microbiome Based Drugs and Diagnostics Market Share by Application (2013-2025)

        1.5.2 Clinical Research Institutes

        1.5.3 Hospital

        1.5.4 Surgical Centers

        1.5.5 Others

    1.6 Study Objectives

    1.7 Years Considered

2 Global Growth Trends

    2.1 Human Microbiome Based Drugs and Diagnostics Market Size

    2.2 Human Microbiome Based Drugs and Diagnostics Growth Trends by Regions

        2.2.1 Human Microbiome Based Drugs and Diagnostics Market Size by Regions (2013-2025)

        2.2.2 Human Microbiome Based Drugs and Diagnostics Market Share by Regions (2013-2018)

    2.3 Industry Trends

        2.3.1 Market Top Trends

        2.3.2 Market Drivers

        2.3.3 Market Opportunities

3 Market Share by Key Players

    3.1 Human Microbiome Based Drugs and Diagnostics Market Size by Manufacturers

        3.1.1 Global Human Microbiome Based Drugs and Diagnostics Revenue by Manufacturers (2013-2018)

        3.1.2 Global Human Microbiome Based Drugs and Diagnostics Revenue Market Share by Manufacturers (2013-2018)

        3.1.3 Global Human Microbiome Based Drugs and Diagnostics Market Concentration Ratio (CR5 and HHI)

    3.2 Human Microbiome Based Drugs and Diagnostics Key Players Head office and Area Served

    3.3 Key Players Human Microbiome Based Drugs and Diagnostics Product/Solution/Service

    3.4 Date of Enter into Human Microbiome Based Drugs and Diagnostics Market

    3.5 Mergers & Acquisitions, Expansion Plans

4 Breakdown Data by Type and Application

    4.1 Global Human Microbiome Based Drugs and Diagnostics Market Size by Type (2013-2018)

    4.2 Global Human Microbiome Based Drugs and Diagnostics Market Size by Application (2013-2018)

5 United States

    5.1 United States Human Microbiome Based Drugs and Diagnostics Market Size (2013-2018)

    5.2 Human Microbiome Based Drugs and Diagnostics Key Players in United States

    5.3 United States Human Microbiome Based Drugs and Diagnostics Market Size by Type

    5.4 United States Human Microbiome Based Drugs and Diagnostics Market Size by Application

6 Europe

    6.1 Europe Human Microbiome Based Drugs and Diagnostics Market Size (2013-2018)

    6.2 Human Microbiome Based Drugs and Diagnostics Key Players in Europe

    6.3 Europe Human Microbiome Based Drugs and Diagnostics Market Size by Type

    6.4 Europe Human Microbiome Based Drugs and Diagnostics Market Size by Application

7 China

    7.1 China Human Microbiome Based Drugs and Diagnostics Market Size (2013-2018)

    7.2 Human Microbiome Based Drugs and Diagnostics Key Players in China

    7.3 China Human Microbiome Based Drugs and Diagnostics Market Size by Type

    7.4 China Human Microbiome Based Drugs and Diagnostics Market Size by Application

8 Japan

    8.1 Japan Human Microbiome Based Drugs and Diagnostics Market Size (2013-2018)

    8.2 Human Microbiome Based Drugs and Diagnostics Key Players in Japan

    8.3 Japan Human Microbiome Based Drugs and Diagnostics Market Size by Type

    8.4 Japan Human Microbiome Based Drugs and Diagnostics Market Size by Application

9 Southeast Asia

    9.1 Southeast Asia Human Microbiome Based Drugs and Diagnostics Market Size (2013-2018)

    9.2 Human Microbiome Based Drugs and Diagnostics Key Players in Southeast Asia

    9.3 Southeast Asia Human Microbiome Based Drugs and Diagnostics Market Size by Type

    9.4 Southeast Asia Human Microbiome Based Drugs and Diagnostics Market Size by Application

10 India

    10.1 India Human Microbiome Based Drugs and Diagnostics Market Size (2013-2018)

    10.2 Human Microbiome Based Drugs and Diagnostics Key Players in India

    10.3 India Human Microbiome Based Drugs and Diagnostics Market Size by Type

    10.4 India Human Microbiome Based Drugs and Diagnostics Market Size by Application

11 Central & South America

    11.1 Central & South America Human Microbiome Based Drugs and Diagnostics Market Size (2013-2018)

    11.2 Human Microbiome Based Drugs and Diagnostics Key Players in Central & South America

    11.3 Central & South America Human Microbiome Based Drugs and Diagnostics Market Size by Type

    11.4 Central & South America Human Microbiome Based Drugs and Diagnostics Market Size by Application

12 International Players Profiles

    12.1 Second Genome Inc.

        12.1.1 Second Genome Inc. Company Details

        12.1.2 Company Description and Business Overview

        12.1.3 Human Microbiome Based Drugs and Diagnostics Introduction

        12.1.4 Second Genome Inc. Revenue in Human Microbiome Based Drugs and Diagnostics Business (2013-2018)

        12.1.5 Second Genome Inc. Recent Development

    12.2 Enterome Bioscience

        12.2.1 Enterome Bioscience Company Details

        12.2.2 Company Description and Business Overview

        12.2.3 Human Microbiome Based Drugs and Diagnostics Introduction

        12.2.4 Enterome Bioscience Revenue in Human Microbiome Based Drugs and Diagnostics Business (2013-2018)

        12.2.5 Enterome Bioscience Recent Development

    12.3 Yakult

        12.3.1 Yakult Company Details

        12.3.2 Company Description and Business Overview

        12.3.3 Human Microbiome Based Drugs and Diagnostics Introduction

        12.3.4 Yakult Revenue in Human Microbiome Based Drugs and Diagnostics Business (2013-2018)

        12.3.5 Yakult Recent Development

    12.4 DuPont

        12.4.1 DuPont Company Details

        12.4.2 Company Description and Business Overview

        12.4.3 Human Microbiome Based Drugs and Diagnostics Introduction

        12.4.4 DuPont Revenue in Human Microbiome Based Drugs and Diagnostics Business (2013-2018)

        12.4.5 DuPont Recent Development

    12.5 Vedanta BioSciences

        12.5.1 Vedanta BioSciences Company Details

        12.5.2 Company Description and Business Overview

        12.5.3 Human Microbiome Based Drugs and Diagnostics Introduction

        12.5.4 Vedanta BioSciences Revenue in Human Microbiome Based Drugs and Diagnostics Business (2013-2018)

        12.5.5 Vedanta BioSciences Recent Development

    12.6 Metabiomics Corporation

        12.6.1 Metabiomics Corporation Company Details

        12.6.2 Company Description and Business Overview

        12.6.3 Human Microbiome Based Drugs and Diagnostics Introduction

        12.6.4 Metabiomics Corporation Revenue in Human Microbiome Based Drugs and Diagnostics Business (2013-2018)

        12.6.5 Metabiomics Corporation Recent Development

    12.7 ViThera Pharmaceuticals

        12.7.1 ViThera Pharmaceuticals Company Details

        12.7.2 Company Description and Business Overview

        12.7.3 Human Microbiome Based Drugs and Diagnostics Introduction

        12.7.4 ViThera Pharmaceuticals Revenue in Human Microbiome Based Drugs and Diagnostics Business (2013-2018)

        12.7.5 ViThera Pharmaceuticals Recent Development

    12.8 MicroBiome Therapeutics LLC

        12.8.1 MicroBiome Therapeutics LLC Company Details

        12.8.2 Company Description and Business Overview

        12.8.3 Human Microbiome Based Drugs and Diagnostics Introduction

        12.8.4 MicroBiome Therapeutics LLC Revenue in Human Microbiome Based Drugs and Diagnostics Business (2013-2018)

        12.8.5 MicroBiome Therapeutics LLC Recent Development

    12.9 Osel

        12.9.1 Osel Company Details

        12.9.2 Company Description and Business Overview

        12.9.3 Human Microbiome Based Drugs and Diagnostics Introduction

        12.9.4 Osel Revenue in Human Microbiome Based Drugs and Diagnostics Business (2013-2018)

        12.9.5 Osel Recent Development

    12.10 Merck

        12.10.1 Merck Company Details

        12.10.2 Company Description and Business Overview

        12.10.3 Human Microbiome Based Drugs and Diagnostics Introduction

        12.10.4 Merck Revenue in Human Microbiome Based Drugs and Diagnostics Business (2013-2018)

        12.10.5 Merck Recent Development

13 Market Forecast 2018-2025

    13.1 Market Size Forecast by Regions

    13.2 United States

    13.3 Europe

    13.4 China

    13.5 Japan

    13.6 Southeast Asia

    13.7 India

    13.8 Central & South America

    13.9 Market Size Forecast by Product (2018-2025)

    13.10 Market Size Forecast by Application (2018-2025)

14 Analyst's Viewpoints/Conclusions

15 Appendix

    15.1 Research Methodology

        15.1.1 Methodology/Research Approach

            15.1.1.1 Research Programs/Design

            15.1.1.2 Market Size Estimation

            12.1.1.3 Market Breakdown and Data Triangulation

        15.1.2 Data Source

            15.1.2.1 Secondary Sources

            15.1.2.2 Primary Sources

    15.2 Disclaimer

    15.3 Author Details